Market Snapshot

Study Period: | 2018 - 2026 |
Base Year: | 2021 |
Fastest Growing Market: | Asia Pacific |
Largest Market: | North America |
CAGR: | 8.74 % |
![]() |
Need a report that reflects how COVID-19 has impacted this market and its growth?
Market Overview
Under the conventional method of toxicity studies, large libraries are screened in search of potential drug candidates. This method is expensive, resource- and time-consuming, and has a low success rate. Consequently, high content screening (HCS) solutions for testing the potential toxicity of chemicals and complex substances are being adopted by pharmaceutical companies to improve in-vitro toxicity testing by reducing the time and cost.
- The need for cost containment in pharmaceutical R&D, advancements in informatics solutions and imaging instruments, and government funding and venture capital investments across developed markets are the major factors driving the growth of the high-content screening (HCS) market.
- The increasing number of contract research organizations providing HCS outsourcing services and the application of HCS in personalized medicine present significant growth opportunities in the market.
Scope of the Report
High content screening (HCS) is a method that is used in biological research and drug discovery to identify substances, such as small molecules, peptides, or RNAi, that alter the phenotype of a cell in the desired manner. High content screening includes any method used to analyze whole cells or components of cells with a simultaneous readout of several parameters.
By Product | |||||
| |||||
| |||||
Software | |||||
Other Products |
By Application | |
Primary and Secondary Screening | |
Target Identification and Validation | |
Toxicity Studies | |
Compound Profiling | |
Other Applications |
By End User | |
Pharmaceutical and Biotechnology Companies | |
Academic and Government Institutions | |
Contract Research Organization |
Geography | ||||||||
| ||||||||
| ||||||||
| ||||||||
| ||||||||
|
Key Market Trends
Instrument Segment is Expected to Lead the Market Over the Forecast Period
Based on the product segment, the high content screening market is further segmented into instruments, consumables, and software and services. Among all high content screening products, the instrument segment occupies the largest share of the market. The large share of this segment is attributed to advances in instrumentation and automation techniques and the high prices of HCS instruments. Companies are developing automated solutions such as instruments with advanced visualization capability, in line with the enhanced software platform. These advances are boosting the market growth. In January 2017, PerkinElmer Inc. launched the Vectra Polaris automated quantitative pathology imaging system. This multi-modal tissue imaging system enables researchers to gain a deeper level of understanding of disease mechanisms related to new cancer immunotherapy approaches. The increasing funds for product development and increasing use of the instruments are boosting the segment.

To understand key trends, Download Sample Report
Asia-Pacific Region is Expected to Attain the Highest Growth Rate Over the Forecast Period
The high content screening market in Asia-Pacific is expected to register the highest CAGR over the forecast period. Factors, such as increasing drug discovery research, government initiatives, growing focus of multinational companies on emerging markets, and developing R&D infrastructure, are driving the growth of the HCS market in this region. Japan and China are expected to witness significant growth during the forecast period, as many research and development programs are carried out by manufacturers to improve the cell analyzers and flow cytometers in the high content screening market.

To understand geography trends, Download Sample Report
Competitive Landscape
For compound profiling applications, many pharmaceutical companies are partnering with contract research organizations to identify potential candidates for drug discovery. The HCS market is highly competitive in nature. The majority of large global players are based out of the United States, and these players have expertise in other biotechnology/medical-technology verticals as well, which helps them in controlling the major market share, through a presence in the allied markets.
Table of Contents
-
1. INTRODUCTION
-
1.1 Study Deliverables
-
1.2 Study Assumptions
-
1.3 Scope of the Study
-
-
2. RESEARCH METHODOLOGY
-
3. EXECUTIVE SUMMARY
-
4. MARKET DYNAMICS
-
4.1 Market Overview
-
4.2 Market Drivers
-
4.2.1 Government Funding and Venture Capital Investments Across Developed Markets
-
4.2.2 Increasing Applications of HCS in Life Science Research
-
4.2.3 Advancements in Informatic Solutions and Imaging Systems
-
-
4.3 Market Restraints
-
4.3.1 Lower Adoption of HCS Instruments Due to Their High Prices
-
-
4.4 Porter's Five Forces Analysis
-
4.4.1 Threat of New Entrants
-
4.4.2 Bargaining Power of Buyers/Consumers
-
4.4.3 Bargaining Power of Suppliers
-
4.4.4 Threat of Substitute Products
-
4.4.5 Intensity of Competitive Rivalry
-
-
-
5. MARKET SEGMENTATION
-
5.1 By Product
-
5.1.1 Instruments
-
5.1.1.1 Cell Imaging and Analysis Systems
-
5.1.1.2 Flow Cytometers
-
-
5.1.2 Consumables
-
5.1.2.1 Reagents and Assay Kits
-
5.1.2.2 Microplates
-
5.1.2.3 Other Consumables
-
-
5.1.3 Software
-
5.1.4 Other Products
-
-
5.2 By Application
-
5.2.1 Primary and Secondary Screening
-
5.2.2 Target Identification and Validation
-
5.2.3 Toxicity Studies
-
5.2.4 Compound Profiling
-
5.2.5 Other Applications
-
-
5.3 By End User
-
5.3.1 Pharmaceutical and Biotechnology Companies
-
5.3.2 Academic and Government Institutions
-
5.3.3 Contract Research Organization
-
-
5.4 Geography
-
5.4.1 North America
-
5.4.1.1 United States
-
5.4.1.2 Canada
-
5.4.1.3 Mexico
-
-
5.4.2 Europe
-
5.4.2.1 Germany
-
5.4.2.2 United Kingdom
-
5.4.2.3 France
-
5.4.2.4 Italy
-
5.4.2.5 Spain
-
5.4.2.6 Rest of Europe
-
-
5.4.3 Asia-Pacific
-
5.4.3.1 China
-
5.4.3.2 Japan
-
5.4.3.3 India
-
5.4.3.4 Australia
-
5.4.3.5 South Korea
-
5.4.3.6 Rest of Asia-Pacific
-
-
5.4.4 Middle-East and Africa
-
5.4.4.1 GCC
-
5.4.4.2 South Africa
-
5.4.4.3 Rest of Middle-East and Africa
-
-
5.4.5 South America
-
5.4.5.1 Brazil
-
5.4.5.2 Argentina
-
5.4.5.3 Rest of South America
-
-
-
-
6. COMPETITIVE LANDSCAPE
-
6.1 Company Profiles
-
6.1.1 GE Healthcare
-
6.1.2 Danaher Corporation
-
6.1.3 Perkinelmer Inc.
-
6.1.4 Thermo Fisher Scientific Inc.
-
6.1.5 Becton, Dickinson and Company
-
6.1.6 Biotek Instruments Inc.
-
6.1.7 Bio-Rad Laboratories Inc.
-
6.1.8 Yokogawa Electric Corporation
-
6.1.9 Merck KGaA
-
*List Not Exhaustive -
-
7. MARKET OPPORTUNITIES AND FUTURE TRENDS
You can also purchase parts of this report. Do you want to check out a section wise price list?
Frequently Asked Questions
What is the study period of this market?
The High Content Screening Market market is studied from 2018 - 2026.
What is the growth rate of High Content Screening Market?
The High Content Screening Market is growing at a CAGR of 8.74% over the next 5 years.
Which region has highest growth rate in High Content Screening Market?
Asia Pacific is growing at the highest CAGR over 2021- 2026.
Which region has largest share in High Content Screening Market?
North America holds highest share in 2021.
Who are the key players in High Content Screening Market?
Becton, Dickinson and Company, Perkinelmer Inc., Danaher Corporation, Thermo Fisher Scientific Inc., GE Healthcare are the major companies operating in High Content Screening Market.